Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Wave Life Sciences cash
Cash and short-term investments held at the end of each period.
Wave Life Sciences's cash was $431.00M at Sep 30, 2026. For fiscal 2025 it was $602.07M, up 99.3% from the year before. Over ten years it grew 14.1% a year on average. The highest annual figure on record is $602.07M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $602.07M | +99.3% |
| FY2024 | Dec 31, 2024 | $302.08M | +50.8% |
| FY2023 | Dec 31, 2023 | $200.35M | +126.4% |
| FY2022 | Dec 31, 2022 | $88.50M | -41.2% |
| FY2021 | Dec 31, 2021 | $150.56M | -18.4% |
| FY2020 | Dec 31, 2020 | $184.50M | +25.4% |
| FY2019 | Dec 31, 2019 | $147.16M | -15.8% |
| FY2018 | Dec 31, 2018 | $174.82M | +22.7% |
| FY2017 | Dec 31, 2017 | $142.50M | -7.4% |
| FY2016 | Dec 31, 2016 | $153.89M | -4.5% |
| FY2015 | Dec 31, 2015 | $161.22M | +15283.6% |
| FY2014 | Dec 31, 2014 | $1.05M | +138.7% |
| FY2013 | Dec 31, 2013 | $439.00K | +15.8% |
| FY2012 | Dec 31, 2012 | $379.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $431.00M | +119.7% |
| Q2 FY2026 | Jun 30, 2026 | $490.60M | +135.3% |
| Q1 FY2026 | Mar 31, 2026 | $544.59M | +124.0% |
| Q4 FY2025 | Dec 31, 2025 | $602.07M | +99.3% |
| Q3 FY2025 | Sep 30, 2025 | $196.22M | -36.9% |
| Q2 FY2025 | Jun 30, 2025 | $208.48M | +35.4% |
| Q1 FY2025 | Mar 31, 2025 | $243.08M | +34.4% |
| Q4 FY2024 | Dec 31, 2024 | $302.08M | +50.8% |
| Q3 FY2024 | Sep 30, 2024 | $310.95M | +122.2% |
| Q2 FY2024 | Jun 30, 2024 | $153.96M | -11.0% |
| Q1 FY2024 | Mar 31, 2024 | $180.92M | -12.8% |
| Q4 FY2023 | Dec 31, 2023 | $200.35M | +126.4% |
| Q3 FY2023 | Sep 30, 2023 | $139.94M | +14.7% |
| Q2 FY2023 | Jun 30, 2023 | $172.97M | +16.7% |
| Q1 FY2023 | Mar 31, 2023 | $207.56M | +85.8% |
| Q4 FY2022 | Dec 31, 2022 | $88.50M | -41.2% |
| Q3 FY2022 | Sep 30, 2022 | $122.00M | -1.5% |
| Q2 FY2022 | Jun 30, 2022 | $148.20M | +3.0% |
| Q1 FY2022 | Mar 31, 2022 | $111.70M | -24.8% |
| Q4 FY2021 | Dec 31, 2021 | $150.56M | -18.4% |
| Q3 FY2021 | Sep 30, 2021 | $123.90M | -42.7% |
| Q2 FY2021 | Jun 30, 2021 | $143.84M | -33.5% |
| Q1 FY2021 | Mar 31, 2021 | $148.54M | +22.8% |
| Q4 FY2020 | Dec 31, 2020 | $184.50M | +25.4% |
| Q3 FY2020 | Sep 30, 2020 | $216.36M | +3.5% |
| Q2 FY2020 | Jun 30, 2020 | $216.40M | -14.4% |
| Q1 FY2020 | Mar 31, 2020 | $120.95M | -57.9% |
| Q4 FY2019 | Dec 31, 2019 | $147.16M | -15.8% |
| Q3 FY2019 | Sep 30, 2019 | $209.01M | -0.7% |
| Q2 FY2019 | Jun 30, 2019 | $252.91M | +4.8% |
| Q1 FY2019 | Mar 31, 2019 | $287.57M | +160.3% |
| Q4 FY2018 | Dec 31, 2018 | $174.82M | +22.7% |
| Q3 FY2018 | Sep 30, 2018 | $210.49M | +24.9% |
| Q2 FY2018 | Jun 30, 2018 | $241.43M | +22.3% |
| Q1 FY2018 | Mar 31, 2018 | $110.49M | -17.0% |
| Q4 FY2017 | Dec 31, 2017 | $142.50M | -7.4% |
| Q3 FY2017 | Sep 30, 2017 | $168.46M | – |
| Q2 FY2017 | Jun 30, 2017 | $197.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $133.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $153.89M | – |
See a number that looks wrong?